Somatostatin Receptor Agonist - Pipeline Insight, 2022

“Somatostatin Receptor Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Somatostatin Receptor Agonist - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Somatostatin Receptor Agonist - Pipeline Insights, 2021 Understanding

Somatostatin Receptor Agonist - Pipeline Insights, 2021: Overview

Somatostatin is a regulatory neuropeptide widely distributed throughout endocrine, neuronal and immune cells of the gastrointestinal tract that exerts a broad spectrum of biological actions under physiological and pathophysiological conditions. Somatostatin actions are mediated by the peptide high affinity to five distinct G-protein-coupled membrane receptors referred to as sst1, sst2, sst3, sst4, and sst5 that are linked with various transduction-signaling pathways.

""Somatostatin Receptor Agonist - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Somatostatin Receptor Agonist - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Somatostatin Receptor Agonist - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Somatostatin Receptor Agonist - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Somatostatin Receptor Agonist - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Somatostatin Receptor Agonist - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Somatostatin Receptor Agonist - Pipeline Insights, 2021.

Somatostatin Receptor Agonist - Pipeline Insights, 2021 Emerging Drugs Chapters

This segment of the Somatostatin Receptor Agonist - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Somatostatin Receptor Agonist - Pipeline Insights, 2021 Emerging Drugs
• Paltusotine: Crinetics Pharmaceuticals

Paltusotine (formerly CRN00808) is an orally available nonpeptide biased agonist that is designed to be highly selective for the somatostatin sst2 receptor. Somatostatin is a neuropeptide hormone that broadly inhibits the secretion of other hormones, including growth hormone, or GH, from the pituitary gland. Acromegaly arises from a benign pituitary tumor that secretes excess GH that in turn causes excess secretion of insulin-like growth factor-1, or IGF-1, by the liver. In July 2020, the U.S. Food and Drug Administration (FDA) granted paltusotine Orphan Drug Designation for the treatment of acromegaly.
• CAM2029: Camurus

CAM2029 is a new ready-to-use, long-acting octreotide drug product being developed for treatment of acromegaly and carcinoid tumours (and other gastro-entero-pancreatic neuroendocrine, GEP-NE, tumours). CAM2029 consists of a lipid-based liquid in a prefilled syringe with a thin needle and it is administered subcutaneously as a low volume injection. CAM2029 has been evaluated in four clinical Phase I and II studies and shown promising results in a Phase II multi-center study in patients with acromegaly and NET. The drug is currently being investigated in Phase II stage of development for the treatment of acromegaly. Camurus intends to Submit NDA in late 2022.

Further product details are provided in the report……..

Somatostatin Receptor Agonist - Pipeline Insights, 2021: Therapeutic Assessment

This segment of the report provides insights about the different Somatostatin Receptor Agonist - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Somatostatin Receptor Agonist - Pipeline Insights, 2021

There are approx. 14+ key companies which are developing the therapies for Somatostatin Receptor Agonist - Pipeline Insights, 2021. The companies which have their Somatostatin Receptor Agonist - Pipeline Insights, 2021 drug candidates in the most advanced stage, i.e. Phase III include, Crinetics Pharmaceuticals.
• Phases

DelveInsight’s report covers around 14+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Somatostatin Receptor Agonist - Pipeline Insights, 2021 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Somatostatin Receptor Agonist - Pipeline Insights, 2021: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Somatostatin Receptor Agonist - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Somatostatin Receptor Agonist - Pipeline Insights, 2021 drugs.

Somatostatin Receptor Agonist - Pipeline Insights, 2021 Report Insights
• Somatostatin Receptor Agonist - Pipeline Insights, 2021 Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Somatostatin Receptor Agonist - Pipeline Insights, 2021 Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Somatostatin Receptor Agonist - Pipeline Insights, 2021 drugs?
• How many Somatostatin Receptor Agonist - Pipeline Insights, 2021 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Somatostatin Receptor Agonist - Pipeline Insights, 2021?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Somatostatin Receptor Agonist - Pipeline Insights, 2021 therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Somatostatin Receptor Agonist - Pipeline Insights, 2021 and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Crinetics Pharmaceuticals
• Camurus
• Strongbridge Biopharma
• Dauntless Pharmaceuticals
• Aquestive Therapeutics

Key Products
• Paltusotine
• CAM2029
• Veldoreotide
• DP1038
• AQST-305